title: Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma.
abstract: BACKGROUND
  Sunitinib is a tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC). Few data evaluated severe buccodental adverse events. The aim of this study was to evaluate sunitinib buccodental toxicity in patients with metastatic RCC and to compare it with that of standard chemotherapy in patients with other solid cancers.
  
  
  METHODS
  Patients with RCC treated with sunitinib and patients with other solid tumours treated with chemotherapy were followed for 3 months. Data on dental appliances, oral hygiene/care practices before and during treatment were collected.
  
  
  RESULTS
  A total of 116 patients were included (58 RCC treated by sunitinib: group S, and 58 treated by chemotherapy: group C). No differences in dental care habits were noted before treatment. In group S, patients reported significantly more frequent pain (P<0.01), teeth instability (P=0.01), gingival bleeding (P=0.01) and change in teeth colour (P=0.02). In all, 58% of patients in this group had to modify their diet (P<0.01). Frequency of dentist visits for teeth removal was increased (25% vs 8%, P=0.01).
  
  
  CONCLUSIONS
  Sunitinib seems to increase buccodental toxicity as compared with chemotherapy. This finding emphasises the need for optimal dental care and standardised dental follow-up in patients treated with sunitinib.
authors.affiliation: 1] Department of Medical Oncology, Paoli-Calmettes Institute, 232 Bd Sainte Marguerite, Marseille 13009, France [2] Unité de Recherche Contre le Cancer, CRCM-INSERM U1068, Faculté de Luminy, Université Aix-Marseille, Marseille 13009, France.
authors.forename: M
authors.initials: M
authors.lastname: Gilabert
authors.forename: M
authors.initials: M
authors.lastname: Provansal
authors.forename: M
authors.initials: M
authors.lastname: Cappiello
authors.forename: Y
authors.initials: Y
authors.lastname: Walz
authors.forename: N
authors.initials: N
authors.lastname: Salem
authors.forename: C
authors.initials: C
authors.lastname: Tarpin
authors.forename: S
authors.initials: S
authors.lastname: Brunelle
authors.forename: J
authors.initials: J
authors.lastname: Thomassin
authors.forename: G
authors.initials: G
authors.lastname: Gravis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009910:Oral Hygiene; D010146:Pain; D010512:Periodontal Index; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D011795:Surveys and Questionnaires; D014085:Tooth Migration / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
references.citation: J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
references.pmid: 16002463
references.citation: Curr Clin Pharmacol. 2008 May;3(2):132-43
references.pmid: 18690886
references.citation: Natl Inst Health Consens Dev Conf Consens Statement. 1989 Apr 17-19;7(7):1-11
references.pmid: 2535680
references.citation: Cancer. 2003 Oct 1;98(7):1531-9
references.pmid: 14508842
references.citation: J Support Oncol. 2007 Oct;5(9 Suppl 4):23-31
references.pmid: 18046995
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jun;115(6):e32-6
references.pmid: 23567260
references.citation: Cancer. 2008 Jan 15;112(2):284-92
references.pmid: 18041060
references.citation: Arch Dermatol. 2008 Jan;144(1):123-5
references.pmid: 18209189
references.citation: Clin Cancer Res. 2003 Jan;9(1):327-37
references.pmid: 12538485
references.citation: Eur Urol. 2011 Apr;59(4):526-40
references.pmid: 21277078
references.citation: Ann Intern Med. 2006 May 16;144(10):753-61
references.pmid: 16702591
references.citation: J Clin Oncol. 2008 Aug 20;26(24):4037-8
references.pmid: 18711196
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4333-8
references.pmid: 19636011
references.citation: Oncology. 2009;76(3):209-11
references.pmid: 19212145
references.citation: J Clin Periodontol. 1990 Aug;17(7 ( Pt 2)):501-3
references.pmid: 2202747
references.citation: Cancer. 2009 May 15;115(10 Suppl):2306-12
references.pmid: 19402073
references.citation: Curr Treat Options Oncol. 2007 Jun;8(3):211-26
references.pmid: 17712534
references.citation: Ann Oncol. 2009 Mar;20(3):600-1
references.pmid: 19188135
references.citation: Oncology (Williston Park). 1991 Dec;5(12):11-8; discussion 18-22
references.pmid: 1840018
references.citation: Bone. 2009 Jan;44(1):173-5
references.pmid: 18849018
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4406-12
references.pmid: 19667267
references.citation: Dent Clin North Am. 2008 Jan;52(1):61-77, viii
references.pmid: 18154865
references.citation: J Natl Cancer Inst Monogr. 2007;(37):39-46
references.pmid: 17951230
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar;113(3):e1-3
references.pmid: 22676833
references.citation: J Endod. 2010 Sep;36(9):1588-92
references.pmid: 20728733
references.citation: J Natl Cancer Inst Monogr. 2007;(37):16-21
references.pmid: 17951226
references.citation: J Clin Oncol. 2007 Mar 1;25(7):884-96
references.pmid: 17327610
references.citation: N Engl J Med. 2007 Apr 12;356(15):1580; author reply 1580-1
references.pmid: 17429091
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references.pmid: 19487381
references.citation: Oncology (Williston Park). 2002 May;16(5):680-6; discussion 686, 691-2, 695
references.pmid: 12108892